Fenelidone (Keshenda) drug interactions and combined drug safety analysis

Finerenone is a new type of non-steroidal selective mineralocorticoid receptor antagonist (MRA), mainly used to treat type 2 diabetes patients with chronic kidney disease (CKD). Its mechanism of action is to block inflammation and fibrosis mediated by mineralocorticoid receptors, thereby delaying the deterioration of renal function and cardiovascular complications. As a new drug approved in recent years, fenelidone has shown good clinical efficacy and tolerability. However, due to its metabolic pathways and pharmacological properties, patients still need to pay special attention to drug interactions during use to ensure the safety and effectiveness of treatment.

1. Metabolic pathways and drug interactions of fenelinone

Fennelidone is mainly metabolized by the hepatic cytochrome P450 enzyme system (CYP3A4). In terms of pharmacokinetics, it is highly dependent on CYP3A4, so when patients use strong inhibitors or inducers of CYP3A4 at the same time, the plasma concentration may change significantly. For example:

Strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, ritonavir, etc.) can significantly increase fenelidone blood levels, thereby increasing the risk of adverse reactions such as hyperkalemia and worsening renal function.

Strong CYP3A4 inducers (such as rifampicin, carbamazepine, phenytoin, St. John's wort) may significantly reduce the plasma concentration of fenelidone, resulting in weakened or even ineffective efficacy.

Therefore, concomitant use with strong CYP3A4 inhibitors or inducers is generally avoided in clinical practice. If a moderate inhibitor must be used, the fenelidone dose adjustment and increased monitoring of serum potassium and renal function may be necessary.

2. Combined use with antihypertensive drugs, diuretics and RAAS inhibitors

Fennelidone is often used in patients with diabetic nephropathy, who often take antihypertensive drugs, diuretics and RAAS inhibitors (ACEI or ARB) in combination. Its interaction and safety analysis are as follows:

1. Combined use with ACEI/ARB: Clinical trial evidence shows that the combination of fenelidone and ACEI or ARB can significantly reduce proteinuria and delay the deterioration of renal function. However, because all three may increase serum potassium levels, patients need to regularly monitor serum potassium, especially at the beginning of treatment and after dose adjustment.

2. Combined use with diuretics: Loop diuretics or thiazide diuretics can reduce blood potassium levels, which can offset the risk of hyperkalemia caused by fenelidone to a certain extent. However, if potassium-sparing diuretics (such as spironolactone, eplerenone, amiloride, etc.) are used together, the risk of hyperkalemia is significantly increased and should be strictly avoided.

3. With calcium channel blockers and beta-blockers: No significant pharmacokinetic interactions have been found so far, but individual patients still need to pay attention to their blood pressure control to avoid hypotension or electrolyte imbalance.

3. Interactions with diabetes medications and anticoagulant drugs

Patients with type 2 diabetes are often treated with oral hypoglycemic drugs or insulin when taking fenelidone.

1. With SGLT2 inhibitors (such as dapagliflozin, empagliflozin): the two have complementary mechanisms of action, and their combined use has shown good renal protection and cardiovascular benefits in clinical trials. No significant pharmacokinetic conflicts have been found, but renal function and fluid balance still need to be paid attention to.

2. With GLP-1 receptor agonists: No direct interaction on drug metabolism has been found, but it may indirectly affect renal function through body fluid balance and blood sugar control, and regular follow-up is required.

3. With oral anticoagulants (such as warfarin, dabigatran, rivaroxaban, etc.): Fenelidone itself does not directly affect the coagulation pathway, but due to the decline in renal function may affect the clearance of anticoagulants, it is necessary to strengthen monitoring of coagulation indicators during combined use, especially when renal function fluctuates.

4. Clinical safety management and personalized medication recommendations

To maximize the efficacy of fenelidone and reduce risks during coadministration, the following safe management measures are critical:

1. Baseline assessment: Before starting fenelidone, serum potassium and glomerular filtration rate (eGFR) should be measured, and the patient's concomitant medications should be recorded.

2. Dynamic monitoring: Serum potassium and eGFR should be measured again at the beginning of treatment (within 2–4 weeks), and then the frequency of follow-up is determined based on the patient's risk stratification. High-risk patients (such as those combined with ACEI/ARB and with high baseline serum potassium) require more frequent monitoring.

3. Avoid high-risk combination use: It is prohibited to use strong CYP3A4 inhibitors/inducers and potassium-sparing diuretics at the same time. For patients who must take moderate CYP3A4 inhibitors, dose reduction and increased follow-up should be considered.

4. Individualized adjustment: If the patient's serum potassium is >5.5 mmol/L, fenelidone should be suspended, and low-dose restarting should be considered after the serum potassium returns to normal; if the eGFR drops significantly, the risk-benefit ratio of the medication needs to be re-evaluated.

5. Patient education: Remind patients to avoid high-potassium foods (such as bananas, orange juice, large amounts of nuts, etc.), and promptly report fatigue, palpitations and other symptoms that may be related to high potassium.

Fennelidone, as a new generation of MRA, has outstanding performance in reducing proteinuria, delaying the progression of diabetic nephropathy and improving cardiovascular prognosis. However, during its treatment, drug interactions require great attention, especially CYP3A4-related drugs and drugs that affect blood potassium levels. Through rational combination of drugs, dynamic monitoring of serum potassium and renal function, and strengthening patient education, the clinical safety and long-term efficacy of fenelidone can be significantly improved.

Reference: https://www.drugs.com/